The exocrine pancreatic function was examined in 20 patient without any detectable gastrointestinal disorder. We used 1 g 4(N-acetyl-L-thyrosil) aminobenzoic acid (ALTAB) an Lundh's test meal containing 25 g lactose, and the test was repeated with 3 g lactase (Galantase). The urine was collected for 6 hours to check PABA excretion in urine. Lactose intolerance was diagnosed in 10 patients on the basis of an increase of H2 in the breath at least 15 ppm after Lundh's test meal and/or diarrhoea after test in two hours if this diarrhoea could be prevented by giving Galantase orally. We measured PABA excretion in patients with and without lactose intolerance after Lundh's test meal: 17.8% (SD = 6.7) and 47% (SD = 13) respectively (p less than 0.001), and after Lundh's test meal with Galantase: 34.3% (SD = 12.7) and 43.6% (SD = 10.9) respectively. The increase after Galantase in the group with lactose intolerance was significant (p less than 0.01).CONCLUSIONS1. Lactose content of Lundh's test meal causes a considerable lactose load in patients with lactose intolerance. 2. Oral lactase enzyme usually normalises the result of ALTAB test. 3. It is necessary to detect lactose intolerance before use of Lundh's test meal.

01 Jan 1989·Therapia Hungarica (English edition)

Galantase (beta-galactosidase) treatment in pediatric practice.

Review

Author: Horn, G ; Horváth, K

The authors diagnosed lactose malabsorption by the breath hydrogen analysis in 11 premature and mature babies, in 16 infants and in 28 children between the ages of 3-18 years. All patients were treated with Galantase (beta-galactosidase). According to the results, Galantase is very effective in splitting of lactose of breast-milk, cow-milk and artificial formulas. Pathological hydrogen increase was not detected during the treatment.

19 Aug 1984·Orvosi hetilapQ4 · MEDICINE

[Phase III clinico-pharmacological study of Galantase in adult lactose intolerance patients].

Q4 · MEDICINE

Article

Author: Beró, T ; Vezekényi, Z ; Nagy, L ; Mózsik, G ; Past, T ; Javor, T ; Tapsonyi, Z ; Ruzsa, C

100 Deals associated with Agalsidase Beta(Nipro ES Pharma)

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lactose Intolerance	Japan	Nipro ES Pharma KK	25 Sep 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis